SCANGOS GEORGE A 4

What Happened

• George A. Scangos, a director of Voyager Therapeutics, received a grant of 30,000 stock options (reported as a derivative award) on June 9, 2026. The Form 4 shows the transaction price as $0.00 (this reflects a non-cash option grant, not a market purchase or sale). No cash value or exercise price is provided in the filing itself.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely filing).
• Transaction type/code: A — Grant/award (derivative).
• Shares/options granted: 30,000 (reported at $0.00).
• Shares/ownership after transaction: Not specified in the provided filing data.
• Footnote: The options were issued under Voyager’s 2025 Stock Incentive Plan per the director compensation policy. Vesting commencement date is the grant date; all underlying shares vest on the earlier of the one-year anniversary of the grant or the next annual meeting of stockholders, subject to Scangos’ continued service (see Footnote F1).
• Remarks: Exhibit 24 (Power of Attorney) attached to the filing.

Context

• This was an equity compensation award to a director, not an open-market purchase or sale. Such grants are typically part of director compensation policies; they do not by themselves indicate buying or selling behavior in the market. The options do not appear to have been exercised or sold as part of this filing.